Slide 1: Full Year Results Presentation
Full Year Results Presentation For the twelve months to 31 March 2016 26 May 2016 David Darling, CEO
Slide 2: FY16 Highlights
02: FY16 HIGHLIGHTS Another Year of Commercial Progress and Growth Particularly in the US Uplift in Commercial Milestone Achievements in Good Commercial Progress Launch of Third Product, Revenue United States in Other Markets Cxbladder Monitor Growing customer Expanded US sales team New Commercial L
Slide 3: Our Strategy
03: OUR STRATEGY Growth Strategy Primarily Focused on the US Market OUR OFFER Delivering innovative solutions for the early detection and better management of bladder cancer Current focus on building suite of Cxbladder diagnostic tests, to help detect and manage bladder cancer Our tests are non-inva
Slide 4: FY16 Revenue
04: FY16 REVENUE Uplift in Product Sales In the past two years, operating revenue has grown from $150,000 OPERATING REVENUE to $4.98 million. 162% increase Continuing growth in product sales, particularly in North America. in operating Includes licence fees from Tolmar Australia following revenue es
Slide 5: FY16 Financial Snapshot
05: FY16 FINANCIAL SNAPSHOT Continuing Investment into Four Strategic Areas PEOPLE FY16 FY15 • Expansion of the USA sales team to 18 executives $NZ’000 $NZ’000 • Increased the commercial, marketing and product Total Revenue and Income 7,193 4,132 development teams in New Zealand Total Expenses 22,87
Slide 6: FY16 Financial Position – Balance Sheet
06: FY16 FINANCIAL POSITION – BALANCE SHEET Capital the Main Source of Funding For Growth Cash and cash equivalents $24.16 million as at 31 FY16 FY15 $NZ’000 $NZ’000 March 2016 Cash, Cash Equivalents and Short 24,160 7,819 Term Deposits Debt free with funding from capital and Trade Receivables, Inve
Slide 7: Primary Focus on US Healthcare Market
07: PRIMARY FOCUS ON US HEALTHCARE MARKET FY16 OBJECTIVE Completed recruitment of 18 specialised sales executives. Build Infrastructure for Growth New personnel are now fully trained and mobilised ACHIEVED: Expand to 18 sales Focused on building relationships with existing and new customers includin
Slide 8: Capture Transformational Customers
08: CAPTURE TRANSFORMATIONAL CUSTOMERS FY16 OBJECTIVE Veterans Administration (VA) Capture Transformational Customers Gained registration on the Federal Supply Schedule ACHIEVED: Complete the Federal Pacific Edge now has the ability to market and sell its Cxbladder products Supply Schedule process t
Slide 9: User Programmes
09: USER PROGRAMMES Increase in User Programmes, Future Focus on Transition to Commercial Customer FY16 OBJECTIVE User Programmes: These are a key component of the adoption of Cxbladder tests by urologists Enhance Awareness and Foster Continued to build the number of User Programmes with a focus on
Slide 10: Other Markets
10: OTHER MARKETS Good Progress in New Zealand, Australia and South East Asia FY16 OBJECTIVE South East Asia: Entered into a User Programme Study with a leading hospital in Singapore earlier in the first half year to generate data specific to Singapore and to enable physicians to Grow Our Internatio
Slide 11: Deliver a 'One Stop Shop' of Cxbladder Products
11: DELIVER A ‘ONE STOP SHOP’ OF CXBLADDER PRODUCTS FY16 OBJECTIVE Cxbladder Triage To be used by clinicians and physicians responsible for the primary NZ Launch Dec 2014 detection of bladder cancer as a frontline tool in the early evaluation IN PROGRESS: Deliver a ‘one stop US Rollout 2015 shop’ of
Slide 12: Launch Products into Market
12: LAUNCH PRODUCTS INTO MARKET FY16 OBJECTIVE Cxbladder Triage available in market in New Zealand from December 2014; Launch into the US commenced in July 2015 ACHIEVED: Launch Cxbladder Triage in the USA A number of leading urologists are currently trialling Cxbladder Triage in their clinical sett
Slide 13: Protect Our Intellectual Property
13: PROTECT OUR INTELLCTUAL PROPERTY FY16 OBJECTIVE PATENTS ACCEPTED/GRANTED FY16 Title Country ONGOING: Protect Pacific Edge’s intellectual property, over a range Gastric Cancer I China of diagnostic technologies, in markets around the world Gastric Cancer II Europe Bladder Cancer Markers Australia
Slide 14: Engage with the People Who Matter
14: ENGAGE WITH THE PEOPLE WHO MATTER Pacific Edge is the leading sponsor of bladdercancer.me, an online referral site to FY16 OBJECTIVE enable patients to seek the most appropriate healthcare providers and solutions, including information on the suite of Cxbladder products ACHIEVED: Launch online p
Slide 15: Strategic Opportunities for Growth
15: STRATEGIC OPPORTUNITIES FOR GROWTH Targeting High Growth Over The Medium Term by Creating More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnos
Slide 16: Looking Forward: Grow the Business
16: LOOKING FORWARD: GROW THE BUSINESS PRIORITIES FOR FY17 MARKETS SALES CHANNELS • US: Remains the primary focus for growth • US sales team to continue targeting large Urology practices and integrated healthcare providers as well as targeted, large Veterans • Australia: Work with Tolmar Australia t
Slide 17: Board and Management
17: BOARD AND MANAGEMENT Providing The Experience and Capability to Deliver on Pacific Edge’s Growth Strategy MANAGEMENT TEAM GOVERNANCE Experienced and knowledgeable in the following areas: Board of Directors Development and international commercialisation of Experience in governance, finance, canc
Slide 18: Question and Answer
QUESTION AND ANSWER Pacific Edge 2016 Full Year Results Presentation
Slide 19: www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Executive Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com Pacific Edge 2016 Full Year Results Presentation
Slide 20: Disclaimer
DISCLAIMER Information The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Pacific Edge Limited . The information in this presen